BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 8896434)

  • 1. FK506 in combination with methotrexate for the prevention of graft-versus-host disease after marrow transplantation from matched unrelated donors.
    Nash RA; Piñeiro LA; Storb R; Deeg HJ; Fitzsimmons WE; Furlong T; Hansen JA; Gooley T; Maher RM; Martin P; McSweeney PA; Sullivan KM; Anasetti C; Fay JW
    Blood; 1996 Nov; 88(9):3634-41. PubMed ID: 8896434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The outcome of unrelated donor bone marrow transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low dose methotrexate for graft-versus-host disease prophylaxis.
    Devine SM; Geller RB; Lin LB; Dix SP; Holland HK; Maurer D; O'Toole K; Keller J; Connaghan DG; Heffner LT; Hillyer CD; Rodey GE; Winton EF; Maher RM; Fitzsimmons WE; Wingard JR
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):25-33. PubMed ID: 9209738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: a single-center study.
    Nash RA; Etzioni R; Storb R; Furlong T; Gooley T; Anasetti C; Appelbaum FR; Doney K; Martin P; Slattery J
    Blood; 1995 Jun; 85(12):3746-53. PubMed ID: 7540071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation.
    Ratanatharathorn V; Nash RA; Przepiorka D; Devine SM; Klein JL; Weisdorf D; Fay JW; Nademanee A; Antin JH; Christiansen NP; van der Jagt R; Herzig RH; Litzow MR; Wolff SN; Longo WL; Petersen FB; Karanes C; Avalos B; Storb R; Buell DN; Maher RM; Fitzsimmons WE; Wingard JR
    Blood; 1998 Oct; 92(7):2303-14. PubMed ID: 9746768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors.
    Nash RA; Antin JH; Karanes C; Fay JW; Avalos BR; Yeager AM; Przepiorka D; Davies S; Petersen FB; Bartels P; Buell D; Fitzsimmons W; Anasetti C; Storb R; Ratanatharathorn V
    Blood; 2000 Sep; 96(6):2062-8. PubMed ID: 10979948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of tacrolimus, methotrexate, and methylprednisolone prevents acute but not chronic graft-versus-host disease in unrelated bone marrow transplantation.
    Ogawa H; Soma T; Hosen N; Tatekawa T; Tsuboi A; Oji Y; Tamaki H; Kawakami M; Ikegame K; Murakami M; Fujioka T; Kim EH; Oka Y; Sugiyama H
    Transplantation; 2002 Jul; 74(2):236-43. PubMed ID: 12151737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prophylaxis with FK-506 for graft-versus-host disease after transplantation of bone marrow from unrelated donors].
    Hamazaki T; Yagi K; Inoue M; Sakata N; Okamura T; Yasui M; Sasabe M; Kishimoto T; Inoue A; Kawa K
    Rinsho Ketsueki; 2000 May; 41(5):430-6. PubMed ID: 10879106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial.
    Walker I; Panzarella T; Couban S; Couture F; Devins G; Elemary M; Gallagher G; Kerr H; Kuruvilla J; Lee SJ; Moore J; Nevill T; Popradi G; Roy J; Schultz KR; Szwajcer D; Toze C; Foley R;
    Lancet Haematol; 2020 Feb; 7(2):e100-e111. PubMed ID: 31958417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation.
    Przepiorka D; Ippoliti C; Khouri I; Woo M; Mehra R; Le Bherz D; Giralt S; Gajewski J; Fischer H; Fritsche H; Deisseroth AB; Cleary K; Champlin R; Besien K; Andersson B; Maher R; Fitzsimmons W
    Blood; 1996 Dec; 88(11):4383-9. PubMed ID: 8943876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FK506 (Tacrolimus) monotherapy for prevention of graft-versus-host disease after histocompatible sibling allogenic bone marrow transplantation.
    Fay JW; Wingard JR; Antin JH; Collins RH; Piñeiro LA; Blazar BR; Saral R; Bierer BE; Przepiorka D; Fitzsimmons WE; Maher RM; Weisdorf DJ
    Blood; 1996 Apr; 87(8):3514-9. PubMed ID: 8605372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
    Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
    Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tacrolimus and methotrexate for the prophylaxis of acute graft-versus-host disease in allogeneic bone marrow transplantation in patients with hematologic malignancies.
    Uberti JP; Silver SM; Adams PT; Jacobson P; Scalzo A; Ratanatharathorn V
    Bone Marrow Transplant; 1997 Jun; 19(12):1233-8. PubMed ID: 9208118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship of tacrolimus (FK506) whole blood concentrations and efficacy and safety after HLA-identical sibling bone marrow transplantation.
    Wingard JR; Nash RA; Przepiorka D; Klein JL; Weisdorf DJ; Fay JW; Zhu J; Maher RM; Fitzsimmons WE; Ratanatharathorn V
    Biol Blood Marrow Transplant; 1998; 4(3):157-63. PubMed ID: 9923414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The outcome of matched unrelated donor bone marrow transplantation in patients with hematologic malignancies using molecular typing for donor selection and graft-versus-host disease prophylaxis regimen of cyclosporine, methotrexate, and prednisone.
    Nademanee A; Schmidt GM; Parker P; Dagis AC; Stein A; Snyder DS; O'Donnell M; Smith EP; Stepan DE; Molina A
    Blood; 1995 Aug; 86(3):1228-34. PubMed ID: 7620176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allogeneic bone marrow transplantation with matched unrelated donors for patients with hematologic malignancies using a preparative regimen of high-dose cyclophosphamide and fractionated total body irradiation.
    Geller RB; Devine SM; O'Toole K; Persons L; Keller J; Mauer D; Holland HK; Dix SP; Piotti M; Redei I; Connaghan G; Heffner LT; Hillyer CD; Waller EK; Winton EF; Wingard JR
    Bone Marrow Transplant; 1997 Aug; 20(3):219-25. PubMed ID: 9257890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation.
    Cutler C; Kim HT; Hochberg E; Ho V; Alyea E; Lee SJ; Fisher DC; Miklos D; Levin J; Sonis S; Soiffer RJ; Antin JH
    Biol Blood Marrow Transplant; 2004 May; 10(5):328-36. PubMed ID: 15111932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) bone marrow transplantation using only pharmacological GVHD prophylaxis.
    Ogawa H; Ikegame K; Kaida K; Yoshihara S; Fujioka T; Taniguchi Y; Tamaki H; Inoue T; Hasei H; Iiboshi Y; Tazuke Y; Kawakami M; Kim EH; Soma T; Inoue T; Kawase I
    Exp Hematol; 2008 Jan; 36(1):1-8. PubMed ID: 17920757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serologically HLA-DR-mismatched unrelated donors might provide a valuable alternative in allogeneic transplantation: experience from a single japanese institution.
    Inamoto Y; Kuwatsuka Y; Oba T; Terakura S; Sugimoto K; Tsujimura A; Takahashi T; Yasuda T; Miyamura K; Kodera Y
    Int J Hematol; 2007 Feb; 85(2):163-9. PubMed ID: 17321996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipients.
    Osunkwo I; Bessmertny O; Harrison L; Cheung YK; Van de Ven C; del Toro G; Garvin J; George D; Bradley MB; Wolownik K; Wischhover C; Levy J; Skerrett D; Cairo MS
    Biol Blood Marrow Transplant; 2004 Apr; 10(4):246-58. PubMed ID: 15077223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation.
    Antin JH; Kim HT; Cutler C; Ho VT; Lee SJ; Miklos DB; Hochberg EP; Wu CJ; Alyea EP; Soiffer RJ
    Blood; 2003 Sep; 102(5):1601-5. PubMed ID: 12730113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.